Brief: Enanta Pharmaceuticals Sees Topline Data From At Least One Phase 2 Study of Zelicapavir in Q3 2024

Enanta Pharmaceuticals

04/01/2024 12:49

Jan 4 (Reuters) - Enanta Pharmaceuticals Inc  ENTA.O :
    * ENANTA PHARMACEUTICALS TO PROVIDE UPDATES ON ITS RESEARCH
AND
DEVELOPMENT PROGRAMS AND 2024 OUTLOOK AT THE 42ND ANNUAL J.P.
MORGAN HEALTHCARE CONFERENCE
    * ENANTA PHARMACEUTICALS INC - ANTICIPATE CHALLENGE STUDY
DATA FOR
EDP-323, AN L-PROTEIN INHIBITOR IN DEVELOPMENT TO TREAT RSV, IN
3Q 2024
    * ENANTA PHARMACEUTICALS: EXPECT TOPLINE DATA FROM AT LEAST
ONE
PHASE 2 STUDY OF ZELICAPAVIR IN 3Q 2024
    * ENANTA PHARMACEUTICALS INC: PLANS TO PURSUE ANY FUTURE
COVID-19
EFFORTS IN CONTEXT OF A COLLABORATION, INCLUDING DEVELOPMENT OF
EDP-235

Source text for Eikon:  ID:nBw9BP7lxa 
Further company coverage:  ENTA.O 

 ((Reuters.Briefs@thomsonreuters.com;))